Ronald Harold Wilfred Cooper
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 5 years
- Director since
- 2024
5 years of board service in total across 2 boards, counting each seat separately. Longest: C4 Therapeutics Inc., 2 years.
Chief executive roles
Weak · grade F
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 15% of the scoring weight is on file.
- Earnings growth 15%
- 0
-87.7% a year in earnings per share
15% of the scoring weight is on file. Figures cover October 2023 – October 2025.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
enGene Therapeutics Inc. June 9, 202699.8%
-
C4 Therapeutics Inc. June 18, 202578.3%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 27, 2024 | enGene Therapeutics Inc. | Open-market purchase | +10,000 | $5.70 | $57,000 |
Questions about Ronald Harold Wilfred Cooper
What boards is Ronald Harold Wilfred Cooper on?
Ronald Harold Wilfred Cooper sits on the boards of C4 Therapeutics Inc. and enGene Therapeutics Inc.
What company is Ronald Harold Wilfred Cooper the CEO of?
Ronald Harold Wilfred Cooper has been Chief Executive Officer of enGene Therapeutics Inc. since July 2024.
How long has Ronald Harold Wilfred Cooper served on boards?
Our records show at least 5 years of board service across 2 boards, the earliest from 2024.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.